Syndax Pharmaceuticals (SNDX) EBT (2016 - 2020)
Historic EBT for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' EBT fell 3980.99% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 2412.97%. This contributed to the annual value of -$318.5 million for FY2024, which is 5239.83% down from last year.
- According to the latest figures from Q4 2020, Syndax Pharmaceuticals' EBT is -$19.9 million, which was down 3980.99% from -$19.9 million recorded in Q3 2020.
- Syndax Pharmaceuticals' EBT's 5-year high stood at -$8.4 million during Q2 2016, with a 5-year trough of -$19.9 million in Q4 2020.
- Its 5-year average for EBT is -$15.4 million, with a median of -$15.1 million in 2017.
- Its EBT has fluctuated over the past 5 years, first crashed by 14593.4% in 2016, then soared by 2652.46% in 2019.
- Syndax Pharmaceuticals' EBT (Quarter) stood at -$10.9 million in 2016, then plummeted by 74.99% to -$19.0 million in 2017, then fell by 1.61% to -$19.3 million in 2018, then rose by 26.52% to -$14.2 million in 2019, then crashed by 39.81% to -$19.9 million in 2020.
- Its EBT was -$19.9 million in Q4 2020, compared to -$19.9 million in Q3 2020 and -$16.6 million in Q2 2020.